APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pulmonary Arterial Hypertension (PAH) Medicine

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Pulmonary Arterial Hypertension (PAH) Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

29 December 2025186 pages

Choose your research edition.

Industry ResearchPulmonary Arterial Hypertension (PAH) Medicine Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Pulmonary Arterial Hypertension (PAH) Medicine Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Pulmonary Arterial Hypertension (PAH) Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pulmonary Arterial Hypertension (PAH) Medicine Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Pulmonary Arterial Hypertension (PAH) Medicine Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Pulmonary Arterial Hypertension (PAH) Medicine market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Pulmonary Arterial Hypertension (PAH) Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pulmonary Arterial Hypertension (PAH) Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pulmonary Arterial Hypertension (PAH) Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Pulmonary Arterial Hypertension (PAH) Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Pulmonary Arterial Hypertension (PAH) Medicine include Actelion Pharmaceuticals, Gilead Sciences, United Therapeutics Corporation, Pfizer and Eli Lilly, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pulmonary Arterial Hypertension (PAH) Medicine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pulmonary Arterial Hypertension (PAH) Medicine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pulmonary Arterial Hypertension (PAH) Medicine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pulmonary Arterial Hypertension (PAH) Medicine market size, projected growth trends, production technologies, key applications, and end-use industries.

Pulmonary Arterial Hypertension (PAH) Medicine Segment by Company

Actelion Pharmaceuticals

Gilead Sciences

United Therapeutics Corporation

Pfizer

Eli Lilly

Pulmonary Arterial Hypertension (PAH) Medicine Segment by Type

Calcium Channel Blockers

Novel Targeted Drugs

Other

Pulmonary Arterial Hypertension (PAH) Medicine Segment by Application

Secondary Pulmonary Hypertension (SPH)

Primary Pulmonary Hypertension (PPH)

Pulmonary Arterial Hypertension (PAH) Medicine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Arterial Hypertension (PAH) Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Arterial Hypertension (PAH) Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Arterial Hypertension (PAH) Medicine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pulmonary Arterial Hypertension (PAH) Medicine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Pulmonary Arterial Hypertension (PAH) Medicine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Pulmonary Arterial Hypertension (PAH) Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Pulmonary Arterial Hypertension (PAH) Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Pulmonary Arterial Hypertension (PAH) Medicine Industry Trends Table 2. Pulmonary Arterial Hypertension (PAH) Medicine Industry Drivers Table 3. Pulmonary Arterial Hypertension (PAH) Medicine Industry Opportunities and Challenges Table 4. Pulmonary Arterial Hypertension (PAH) Medicine Industry Restraints Table 5. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Manufacturers Table 9. Global Pulmonary Arterial Hypertension (PAH) Medicine Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Pulmonary Arterial Hypertension (PAH) Medicine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Pulmonary Arterial Hypertension (PAH) Medicine Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Pulmonary Arterial Hypertension (PAH) Medicine Manufacturers, Product Type & Application Table 13. Global Pulmonary Arterial Hypertension (PAH) Medicine Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Pulmonary Arterial Hypertension (PAH) Medicine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Calcium Channel Blockers Table 17. Major Manufacturers of Novel Targeted Drugs Table 18. Major Manufacturers of Other Table 19. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2021-2026) & (K Units) Table 21. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2027-2032) & (K Units) Table 22. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Type (2021-2026) Table 23. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Type (2027-2032) Table 24. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Type (2021-2026) & (K Units) Table 26. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Type (2027-2032) & (K Units) Table 27. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Type (2021-2026) Table 28. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Secondary Pulmonary Hypertension (SPH) Table 30. Major Manufacturers of Primary Pulmonary Hypertension (PPH) Table 31. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2021-2026) & (K Units) Table 33. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2027-2032) & (K Units) Table 34. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Application (2021-2026) Table 35. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Application (2027-2032) Table 36. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Application (2021-2026) & (K Units) Table 38. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Application (2027-2032) & (K Units) Table 39. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Application (2021-2026) Table 40. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Application (2027-2032) Table 41. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region (2021-2026) & (K Units) Table 43. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Region (2021-2026) Table 44. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Pulmonary Arterial Hypertension (PAH) Medicine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2021-2026) & (K Units) Table 48. North America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2027-2032) & (K Units) Table 49. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2021-2026) & (K Units) Table 51. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2027-2032) & (K Units) Table 58. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Region (2021-2026) Table 62. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Region (2027-2032) Table 63. Actelion Pharmaceuticals Company Information Table 64. Actelion Pharmaceuticals Business Overview Table 65. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio Table 67. Actelion Pharmaceuticals Recent Development Table 68. Gilead Sciences Company Information Table 69. Gilead Sciences Business Overview Table 70. Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio Table 72. Gilead Sciences Recent Development Table 73. United Therapeutics Corporation Company Information Table 74. United Therapeutics Corporation Business Overview Table 75. United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio Table 77. United Therapeutics Corporation Recent Development Table 78. Pfizer Company Information Table 79. Pfizer Business Overview Table 80. Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio Table 82. Pfizer Recent Development Table 83. Eli Lilly Company Information Table 84. Eli Lilly Business Overview Table 85. Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio Table 87. Eli Lilly Recent Development Table 88. Key Raw Materials Table 89. Raw Materials Key Suppliers Table 90. Pulmonary Arterial Hypertension (PAH) Medicine Distributors List Table 91. Pulmonary Arterial Hypertension (PAH) Medicine Customers List Table 92. Research Programs/Design for This Report Table 93. Authors List of This Report Table 94. Secondary Sources Table 95. Primary Sources List of Figures Figure 1. Pulmonary Arterial Hypertension (PAH) Medicine Product Image Figure 2. Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size (2021-2032) & (US$ Million) Figure 4. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales (2021-2032) & (K Units) Figure 5. Global Pulmonary Arterial Hypertension (PAH) Medicine Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Pulmonary Arterial Hypertension (PAH) Medicine Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Calcium Channel Blockers Image Figure 9. Novel Targeted Drugs Image Figure 10. Other Image Figure 11. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Type (2021-2032) Figure 14. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Type (2021-2032) Figure 17. Secondary Pulmonary Hypertension (SPH) Image Figure 18. Primary Pulmonary Hypertension (PPH) Image Figure 19. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Application (2021-2032) Figure 22. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Application (2021-2032) Figure 25. North America Pulmonary Arterial Hypertension (PAH) Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Country (2021-2032) Figure 27. U.S. Pulmonary Arterial Hypertension (PAH) Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Pulmonary Arterial Hypertension (PAH) Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Pulmonary Arterial Hypertension (PAH) Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Country (2021-2032) Figure 32. Germany Pulmonary Arterial Hypertension (PAH) Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Pulmonary Arterial Hypertension (PAH) Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Pulmonary Arterial Hypertension (PAH) Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Pulmonary Arterial Hypertension (PAH) Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Pulmonary Arterial Hypertension (PAH) Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Country (2021-2032) Figure 39. China Pulmonary Arterial Hypertension (PAH) Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Pulmonary Arterial Hypertension (PAH) Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Pulmonary Arterial Hypertension (PAH) Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Pulmonary Arterial Hypertension (PAH) Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Pulmonary Arterial Hypertension (PAH) Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Pulmonary Arterial Hypertension (PAH) Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Country (2021-2032) Figure 47. Brazil Pulmonary Arterial Hypertension (PAH) Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Pulmonary Arterial Hypertension (PAH) Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Pulmonary Arterial Hypertension (PAH) Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Pulmonary Arterial Hypertension (PAH) Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Pulmonary Arterial Hypertension (PAH) Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Pulmonary Arterial Hypertension (PAH) Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Pulmonary Arterial Hypertension (PAH) Medicine Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Pulmonary Arterial Hypertension (PAH) Medicine Revenue (2021-2032) & (US$ Million) Figure 58. North America Pulmonary Arterial Hypertension (PAH) Medicine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Pulmonary Arterial Hypertension (PAH) Medicine Revenue (2021-2032) & (US$ Million) Figure 60. Europe Pulmonary Arterial Hypertension (PAH) Medicine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Pulmonary Arterial Hypertension (PAH) Medicine Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Pulmonary Arterial Hypertension (PAH) Medicine Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Calcium Channel Blockers
  • Novel Targeted Drugs
  • Other
Applications
  • Secondary Pulmonary Hypertension (SPH)
  • Primary Pulmonary Hypertension (PPH)
Companies covered
  • Actelion Pharmaceuticals
  • Gilead Sciences
  • United Therapeutics Corporation
  • Pfizer
  • Eli Lilly

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Dynamics
  1. 2.1 Pulmonary Arterial Hypertension (PAH) Medicine Industry Trends
  2. 2.2 Pulmonary Arterial Hypertension (PAH) Medicine Industry Drivers
  3. 2.3 Pulmonary Arterial Hypertension (PAH) Medicine Industry Opportunities and Challenges
  4. 2.4 Pulmonary Arterial Hypertension (PAH) Medicine Industry Restraints
3 Pulmonary Arterial Hypertension (PAH) Medicine Market by Manufacturers
  1. 3.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Manufacturers (2021-2026)
  3. 3.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Pulmonary Arterial Hypertension (PAH) Medicine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Pulmonary Arterial Hypertension (PAH) Medicine Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Pulmonary Arterial Hypertension (PAH) Medicine Manufacturers, Product Type & Application
  7. 3.7 Global Pulmonary Arterial Hypertension (PAH) Medicine Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Pulmonary Arterial Hypertension (PAH) Medicine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Pulmonary Arterial Hypertension (PAH) Medicine Tier 1, Tier 2, and Tier 3
4 Pulmonary Arterial Hypertension (PAH) Medicine Market by Type
  1. 4.1 Pulmonary Arterial Hypertension (PAH) Medicine Type Introduction
  2. 4.1.1 Calcium Channel Blockers
  3. 4.1.2 Novel Targeted Drugs
  4. 4.1.3 Other
  5. 4.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type
  6. 4.2.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Type (2021-2032)
  8. 4.2.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Type (2021-2032)
  9. 4.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Type
  10. 4.3.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Type (2021-2032)
  12. 4.3.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Type (2021-2032)
5 Pulmonary Arterial Hypertension (PAH) Medicine Market by Application
  1. 5.1 Pulmonary Arterial Hypertension (PAH) Medicine Application Introduction
  2. 5.1.1 Secondary Pulmonary Hypertension (SPH)
  3. 5.1.2 Primary Pulmonary Hypertension (PPH)
  4. 5.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application
  5. 5.2.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Application (2021-2032)
  7. 5.2.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Application (2021-2032)
  8. 5.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Application
  9. 5.3.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Application (2021-2032)
  11. 5.3.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Application (2021-2032)
6 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region
  1. 6.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region (2021-2032)
  3. 6.2.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region (2021-2026)
  4. 6.2.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Pulmonary Arterial Hypertension (PAH) Medicine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Region
  1. 7.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Region
  2. 7.1.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Region (2021-2026)
  4. 7.1.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Region (2027-2032)
  5. 7.1.4 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Pulmonary Arterial Hypertension (PAH) Medicine Revenue (2021-2032)
  8. 7.2.2 North America Pulmonary Arterial Hypertension (PAH) Medicine Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Pulmonary Arterial Hypertension (PAH) Medicine Revenue (2021-2032)
  11. 7.3.2 Europe Pulmonary Arterial Hypertension (PAH) Medicine Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Actelion Pharmaceuticals
  2. 8.1.1 Actelion Pharmaceuticals Company Information
  3. 8.1.2 Actelion Pharmaceuticals Business Overview
  4. 8.1.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio
  6. 8.1.5 Actelion Pharmaceuticals Recent Developments
  7. 8.2 Gilead Sciences
  8. 8.2.1 Gilead Sciences Company Information
  9. 8.2.2 Gilead Sciences Business Overview
  10. 8.2.3 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio
  12. 8.2.5 Gilead Sciences Recent Developments
  13. 8.3 United Therapeutics Corporation
  14. 8.3.1 United Therapeutics Corporation Company Information
  15. 8.3.2 United Therapeutics Corporation Business Overview
  16. 8.3.3 United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio
  18. 8.3.5 United Therapeutics Corporation Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 Eli Lilly
  26. 8.5.1 Eli Lilly Company Information
  27. 8.5.2 Eli Lilly Business Overview
  28. 8.5.3 Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio
  30. 8.5.5 Eli Lilly Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pulmonary Arterial Hypertension (PAH) Medicine Value Chain Analysis
  2. 9.1.1 Pulmonary Arterial Hypertension (PAH) Medicine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pulmonary Arterial Hypertension (PAH) Medicine Production Mode & Process
  6. 9.2 Pulmonary Arterial Hypertension (PAH) Medicine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pulmonary Arterial Hypertension (PAH) Medicine Distributors
  9. 9.2.3 Pulmonary Arterial Hypertension (PAH) Medicine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst